H1 2024 consolidated revenue rose 3.5% YoY to KRW 2,949.6 billion, with net profit surging 351.9% due to non-recurring gains, while operating profit fell 54.0% on higher costs. The group strengthened its portfolio with acquisitions, new bond issues, and continued R&D in bio and pharma.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.